Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
Investigational BAY 2927088 is an oral, small molecule, tyrosine kinase inhibitor as a potential new targeted therapy for patients with non-small cell lung cancer (NSCLC) harboring HER2 activating ...
Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...
The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
Many people are familiar with histamine, a biological molecule, that serves as a key driver of allergic reactions and other immune responses. However ...
Using ribosome engineering (RE), researchers from Shinshu University introduced mutations affecting the protein synthesis ...
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
7don MSN
Scientists report new immune insights and targets into LRRK2 mutations in Parkinson's disease
Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder caused by the loss of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback